drugset / Trial / NCT06278038

Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Venlafaxine Hydrochloride Sustained-release Tablets in Patients With Major Depression Disorder

NCT06278038

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate efficacy and safety of toludesvenlafaxine hydrochloride sustained-release tablets in the treatment of major depression disorder compared to venlafaxine hydrochloride sustained-release tablets, to provide evidence-based basis for clinical rational drug use.

Timeline

Start
2024-02-22
Primary completion
2024-11-10
Completion
2024-11-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Toludesvenlafaxine Small molecule 80 mg Oral
Subject Toludesvenlafaxine Small molecule 120 mg Oral
Subject Toludesvenlafaxine Small molecule 160 mg Oral
Comparator Venlafaxine Small molecule 75 mg Oral
Comparator Venlafaxine Small molecule 150 mg Oral
Comparator Venlafaxine Small molecule 225 mg Oral